Rekah Pharmaceutical Industry Management
Management criteria checks 3/4
Rekah Pharmaceutical Industry's CEO is Mordechai Elgrabli, appointed in Apr 2015, has a tenure of 30.67 years. total yearly compensation is ₪845.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 15.32% of the company’s shares, worth ₪22.92M. The average tenure of the management team and the board of directors is 7.2 years and 9 years respectively.
Key information
Mordechai Elgrabli
Chief executive officer
₪845.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 9yrs |
| CEO ownership | 15.3% |
| Management average tenure | 7.2yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -₪7m |
| Sep 30 2023 | n/a | n/a | -₪8m |
| Jun 30 2023 | n/a | n/a | -₪3m |
| Mar 31 2023 | n/a | n/a | -₪2m |
| Dec 31 2022 | ₪845k | ₪845k | -₪2m |
| Sep 30 2022 | n/a | n/a | ₪4m |
| Jun 30 2022 | n/a | n/a | ₪3m |
| Mar 31 2022 | n/a | n/a | ₪5m |
| Dec 31 2021 | ₪830k | ₪830k | ₪7m |
| Sep 30 2021 | n/a | n/a | ₪5m |
| Jun 30 2021 | n/a | n/a | ₪9m |
| Mar 31 2021 | n/a | n/a | ₪10m |
| Dec 31 2020 | ₪828k | ₪828k | ₪11m |
| Sep 30 2020 | n/a | n/a | ₪7m |
| Jun 30 2020 | n/a | n/a | ₪5m |
| Mar 31 2020 | n/a | n/a | ₪4m |
| Dec 31 2019 | ₪832k | ₪832k | ₪3m |
| Sep 30 2019 | n/a | n/a | ₪6m |
| Jun 30 2019 | n/a | n/a | ₪5m |
| Mar 31 2019 | n/a | n/a | ₪7m |
| Dec 31 2018 | ₪801k | ₪801k | ₪8m |
| Sep 30 2018 | n/a | n/a | ₪246k |
| Jun 30 2018 | n/a | n/a | -₪8m |
| Mar 31 2018 | n/a | n/a | -₪11m |
| Dec 31 2017 | ₪795k | ₪795k | -₪21m |
Compensation vs Market: Mordechai's total compensation ($USD222.60K) is below average for companies of similar size in the IL market ($USD431.63K).
Compensation vs Earnings: Mordechai's compensation has increased whilst the company is unprofitable.
CEO
Mordechai Elgrabli (79 yo)
9yrs
Tenure
₪845,000
Compensation
Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9yrs | ₪845.00k | 15.32% ₪ 22.9m | |
| Chief Financial Officer | 5.4yrs | ₪735.00k | no data | |
| Director of Industrial Division & Director | no data | ₪1.21m | 15.32% ₪ 22.9m | |
| Chief Executive Officer of Ophir Shalpharm | no data | ₪693.00k | no data | |
| Director of Operations | no data | ₪684.00k | no data | |
| Deputy CEO & Director of Business Development | 13.1yrs | no data | no data | |
| Chief Executive Officer of Ophir & Shalpharm Ltd | no data | ₪705.00k | 0.026% ₪ 39.3k | |
| Chief Executive Officer - Fresh of Life Pharma Ltd. | 2.5yrs | no data | no data |
7.2yrs
Average Tenure
65yo
Average Age
Experienced Management: REKA's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 30.7yrs | ₪845.00k | 15.32% ₪ 22.9m | |
| Director of Industrial Division & Director | 30.7yrs | ₪1.21m | 15.32% ₪ 22.9m | |
| Director | 9yrs | no data | no data | |
| Chairman | 9yrs | ₪259.00k | no data | |
| Independent External Director | 9yrs | no data | no data | |
| Director | 9yrs | no data | no data | |
| Independent External Director | 7.4yrs | no data | no data | |
| Independent External Director | 7.4yrs | no data | no data |
9.0yrs
Average Tenure
66.5yo
Average Age
Experienced Board: REKA's board of directors are considered experienced (9 years average tenure).